Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 66Lymphoma 55Multiple Myeloma 54Breast Neoplasms 52Neoplasm Metastasis 48Prostatic Neoplasms 46Lung Neoplasms 46Leukemia, Myeloid, Acute 39Ovarian Neoplasms 38Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 33Pancreatic Neoplasms 28Glioma 28Lymphoma, Non-Hodgkin 26Sarcoma 25Urinary Bladder Neoplasms 24Carcinoma, Renal Cell 24Brain Neoplasms 24Neuroblastoma 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Leukemia, Lymphocytic, Chronic, B-Cell 18Stomach Neoplasms 17Small Cell Lung Carcinoma 17Burkitt Lymphoma 17Squamous Cell Carcinoma of Head and Neck 16Glioblastoma 16

Interventions

Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hearing Loss × 90 days × Clear all
NCT04915183 2026-05-22

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡